Literature DB >> 29671505

Care of the Colorectal Cancer Survivor.

Kristina Burgers1, Clint Moore2, Lori Bednash3.   

Abstract

Colorectal cancer is the fourth most common cancer in the United States and has a five-year survival rate of 65%. The American Cancer Society and other experts have released guidelines on surveillance, health promotion, screening for other malignancies, and management of treatment effects. Surveillance for disease recurrence should occur every three to six months for the first two to three years, then every six months for a total of five years. Each visit should include a history and physical examination, routine care for chronic medical conditions, and screening for other primary cancers according to guidelines for the general population. Topics addressed depend on the treatment utilized but generally include gastrointestinal issues, neuropathy, pain, urinary symptoms, fatigue, psychological issues, cognitive problems, sexual symptoms, and stoma care. Carcinoembryonic antigen testing should be performed at each visit in patients who are candidates for further intervention. Chest, abdomen, and pelvic computed tomography should be performed annually for five years after treatment. Colonoscopy should be repeated one year after treatment, then three years later if no advanced adenoma is identified.

Entities:  

Mesh:

Year:  2018        PMID: 29671505

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  6 in total

1.  Knowledge, attitudes, practices, and related factors of low anterior resection syndrome management among colorectal surgery nurses: a multicenter cross-sectional study.

Authors:  Jieman Hu; Jianan Sun; Yanjun Wang; Xuan Sun; Weihua Tong; Haiyan Hu
Journal:  Support Care Cancer       Date:  2021-01-06       Impact factor: 3.359

2.  METTL3 promotes colorectal carcinoma progression by regulating the m6A-CRB3-Hippo axis.

Authors:  Jiashu Pan; Feng Liu; Xiaoli Xiao; Ruohui Xu; Liang Dai; Mingzhe Zhu; Hanchen Xu; Yangxian Xu; Aiguang Zhao; Wenjun Zhou; Yanqi Dang; Guang Ji
Journal:  J Exp Clin Cancer Res       Date:  2022-01-10

3.  CircRNA_0084927 promotes colorectal cancer progression by regulating miRNA-20b-3p/glutathione S-transferase mu 5 axis.

Authors:  Feng Liu; Xiao-Li Xiao; Yu-Jing Liu; Ruo-Hui Xu; Wen-Jun Zhou; Han-Chen Xu; Ai-Guang Zhao; Yang-Xian Xu; Yan-Qi Dang; Guang Ji
Journal:  World J Gastroenterol       Date:  2021-09-28       Impact factor: 5.742

4.  Chemosensitivity analysis and study of gene resistance on tumors and cancer stem cell isolates from patients with colorectal cancer.

Authors:  Elsa N Garza-Treviño; Herminia G Martínez-Rodríguez; Paulina Delgado-González; Orlando Solís-Coronado; Rocio Ortíz-Lopez; Adolfo Soto-Domínguez; Víctor M Treviño; Gerardo R Padilla-Rivas; Jose F Islas-Cisneros; Adriana G Quiroz-Reyes; Salvador L Said-Fernández
Journal:  Mol Med Rep       Date:  2021-08-13       Impact factor: 2.952

5.  Biochanin A Suppresses Tumor Progression and PD-L1 Expression via Inhibiting ZEB1 Expression in Colorectal Cancer.

Authors:  Junying Xu; Xuejing Yang; Jiadong Pan; Honghong Fan; Jie Mei; Dong Hua
Journal:  J Oncol       Date:  2022-02-22       Impact factor: 4.375

6.  METTL3 dual regulation of the stability of LINC00662 and VEGFA RNAs promotes colorectal cancer angiogenesis.

Authors:  Guoying Zhang; Tianjun Wang; Zihui Huang; Yuanyuan Chen; Li Sun; Xia Xia; Fang He; Chenying Fan; Shukui Wang; Wanli Liu
Journal:  Discov Oncol       Date:  2022-09-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.